SAN

101.08

+2.18%↑

EI

256

-3.51%↓

SHL.DE

48.16

-2.77%↓

ARGX

545

+3.69%↑

FRE

39.72

+2.8%↑

SAN

101.08

+2.18%↑

EI

256

-3.51%↓

SHL.DE

48.16

-2.77%↓

ARGX

545

+3.69%↑

FRE

39.72

+2.8%↑

SAN

101.08

+2.18%↑

EI

256

-3.51%↓

SHL.DE

48.16

-2.77%↓

ARGX

545

+3.69%↑

FRE

39.72

+2.8%↑

SAN

101.08

+2.18%↑

EI

256

-3.51%↓

SHL.DE

48.16

-2.77%↓

ARGX

545

+3.69%↑

FRE

39.72

+2.8%↑

SAN

101.08

+2.18%↑

EI

256

-3.51%↓

SHL.DE

48.16

-2.77%↓

ARGX

545

+3.69%↑

FRE

39.72

+2.8%↑

Search

Valneva SE

Abrir

3.2 -0.62

Visão Geral

Variação de preço das ações

24h

Atual

Mín

3.09

Máximo

3.25

Indicadores-chave

By Trading Economics

Rendimento

-28M

-37M

Vendas

7.1M

53M

EPS

-0.25

Margem de lucro

-69.865

Funcionários

713

EBITDA

-19M

-26M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+78.13% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-64M

513M

Abertura anterior

3.82

Fecho anterior

3.2

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Valneva SE Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

15 de nov. de 2024, 10:28 UTC

Grandes Movimentos do Mercado

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

3 de set. de 2024, 10:28 UTC

Ganhos

Pfizer, Valneva Report Positive Lyme Disease Vaccine Candidate Data

15 de nov. de 2024, 10:34 UTC

Conversa de Mercado

Vaccine Sector Sell-Off Looks Overdone -- Market Talk

3 de set. de 2024, 10:31 UTC

Conversa de Mercado

Valneva Shares Gain on Positive Vaccine News -- Market Talk

Comparação entre Pares

Variação de preço

Valneva SE Previsão

Preço-alvo

By TipRanks

78.13% parte superior

Previsão para 12 meses

Média 5.7 EUR  78.13%

Máximo 8.1 EUR

Mínimo 3.3 EUR

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Valneva SE - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

1

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

3.2 / 3.32Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Strong Bullish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Valneva SE

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.